PeriodontitisNCT07827391
A Retrospective Comparative Evaluation of Omega-3 and Resveratrol Supplementation in Patients With Periodontitis
An observational study of Periodontitis, run by Izmir Katip Celebi University at 1 site in Turkey (Türkiye).
Trial summary
This retrospective comparative study aims to evaluate the association of adjunctive resveratrol and omega-3 supplementation with clinical periodontal parameters in patients with periodontitis who received non-surgical periodontal treatment. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Periodontitis
- What is being tested?
- trans-resveratrol, Omega-3 (EPA+DHA) and No supplementation
- How many people
- 60 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jan 2025to 15 Mar 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population consists of patients aged 18-65 years who were diagnosed with periodontitis and met the predefined eligibility criteria. A total of 60 patients were included in the study and categorized into three groups according to their recorded supplementation status: a trans-resveratrol supplementation group, an omega-3 supplementation group, and a non-supplemented control group receiving non-surgical periodontal treatment without resveratrol or omega-3 supplementation. All patients received non-surgical periodontal treatment.
Who may be able to join
- Presence of at least 20 natural permanent teeth,
- Age between 18 and 65 years,
- Non-smoker status,
- No use of antibiotics, anti-inflammatory drugs, or systemic corticosteroids within the previous 6 months,
- No known history of hypersensitivity or allergic reactions to resveratrol, omega-3 fatty acids, or dietary supplements containing these components,
- No periodontal treatment within the previous 6 months,
- Absence of any oral or other systemic disease,
- Not being pregnant or lactating.
Who cannot join
- Presence of fewer than 20 natural permanent teeth,
- Age younger than 18 years or older than 65 years,
- Current smoking,
- Use of antibiotics, anti-inflammatory drugs, or systemic corticosteroids within the previous 6 months,
- Known hypersensitivity or allergic reactions to resveratrol, omega-3 fatty acids, or dietary supplements containing these components,
- Periodontal treatment within the previous 6 months,
- Presence of any oral or systemic disease,
- Pregnancy or lactation.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
İzmir Katip Çelebi University, Faculty of Dentistry
Izmir, İzmir, 35640
About this study
Official title: A Retrospective Comparative Evaluation of the Effects of Adjunctive Omega-3 and Resveratrol Supplementation to Non-Surgical Periodontal Therapy on Clinical Periodontal Parameters in Systemically Healthy Patients With Periodontitis.
This retrospective comparative study aims to evaluate the association of adjunctive resveratrol and omega-3 supplementation with clinical periodontal parameters in patients with periodontitis who received non-surgical periodontal treatment. A total of 60 systemically healthy, non-smoking patients will be evaluated based on their clinical records and categorized into three groups according to their documented supplementation status: a resveratrol group that received non-surgical periodontal treatment with adjunctive resveratrol supplementation (n=20), an omega-3 group that received non-surgical periodontal treatment with adjunctive omega-3 supplementation (n=20), and a non-supplemented group that received non-surgical periodontal treatment alone (n=20). Clinical periodontal parameters, including probing pocket depth, clinical attachment level, plaque index, gingival index, and bleeding on probing, will be evaluated at baseline and at 1 and 3 months after non-surgical periodontal treatment. The study aims to compare clinical periodontal outcomes among the three groups and to assess whether adjunctive resveratrol or omega-3 supplementation is associated with differences in clinical periodontal parameters compared with non-surgical periodontal treatment alone.
Read the detailed description
This retrospective comparative study aims to evaluate the association of resveratrol and omega-3 supplementation, administered as adjuncts to non-surgical periodontal treatment, with clinical periodontal outcomes in patients with periodontitis. The study also aims to compare the clinical periodontal outcomes associated with these two supplementation approaches with those observed following non-surgical periodontal treatment without supplementation and to compare the two supplementation groups with each other.
Periodontitis is a chronic inflammatory disease in which microbial dental biofilm and the host inflammatory response contribute to periodontal tissue breakdown. Accordingly, periodontal treatment primarily aims to control the subgingival microbial burden and reduce periodontal inflammation, thereby improving clinical periodontal conditions. In addition to mechanical periodontal treatment, adjunctive approaches with anti-inflammatory and antioxidant properties have been investigated for their potential association with differences in clinical periodontal outcomes.
Omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been investigated in the context of periodontal inflammation. These fatty acids may influence inflammatory processes and the resolution of inflammation through their involvement in the production of lipid mediators, including specialized pro-resolving mediators such as resolvins, protectins, and maresins. Resveratrol is a naturally occurring polyphenolic compound with reported antioxidant and anti-inflammatory properties. Its potential biological effects have been associated with the regulation of inflammatory signaling pathways and oxidative stress. These biological properties provide a rationale for investigating the clinical periodontal outcomes associated with resveratrol and omega-3 supplementation when used as adjuncts to non-surgical periodontal treatment.
Clinical records of 60 systemically healthy, non-smoking patients diagnosed with periodontitis will be retrospectively reviewed. Based on the documented supplementation status in their clinical records, patients will be classified into three groups, with 20 patients in each group. The resveratrol group will consist of patients who received resveratrol supplementation in addition to non-surgical periodontal treatment. The omega-3 group will consist of patients who received omega-3 supplementation in addition to non-surgical periodontal treatment. The non-supplemented control group will consist of patients who received non-surgical periodontal treatment alone.
Patients with a history of periodontal treatment within the previous 6 months, use of antibiotics, anti-inflammatory agents, or systemic corticosteroids within the previous 6 months, or a history of systemic disease will be excluded from the study.
Clinical periodontal parameters recorded at baseline and at 1 and 3 months after non-surgical periodontal treatment will be evaluated. The evaluated parameters will include probing pocket depth, clinical attachment level, plaque index, gingival index, and bleeding on probing.
The primary objective of the study is to compare clinical periodontal outcomes among the resveratrol, omega-3, and non-supplemented control groups. The study will also evaluate whether adjunctive resveratrol or omega-3 supplementation is associated with differences in clinical periodontal outcomes compared with non-surgical periodontal treatment alone. In addition, the study will compare clinical periodontal outcomes between the resveratrol and omega-3 supplementation groups. The study will provide a clinical comparison of periodontal outcomes among patients receiving non-surgical periodontal treatment with or without adjunctive supplementation.
- Conditions
- Periodontitis
- Being tested
- trans-resveratrol, Omega-3 (EPA+DHA), No supplementation
- Keywords
- Resveratrol, Omega-3 fatty acid, Periodontitis, Non-surgical periodontal treatment, Clinical attachment level
- Medical subject headings
- Periodontitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
trans-resveratrolDietary supplement
Trans-resveratrol supplementation at a dose of 250 mg twice daily (500 mg/day total) during non-surgical periodontal treatment.
Omega-3 (EPA+DHA)Dietary supplement
Omega-3 fatty acid supplementation at a total daily dose of 1320 mg, including 640 mg EPA and 480 mg DHA, during non-surgical periodontal treatment.
No supplementationDietary supplement
Patients who underwent non-surgical periodontal treatment without receiving resveratrol or omega-3 fatty acid supplementation during the treatment period
| Study group | Role | What they receive |
|---|---|---|
| Trans-resveratrol | Patients who received trans-resveratrol supplementation at a dose of 250 mg twice daily (500 mg/day total) as an adjunct to non-surgical periodontal treatment. Receives: Dietary Supplement: trans-resveratrol | |
| Omega-3 fatty acids | Patients who received omega-3 fatty acid supplementation at a total dose of 1320 mg, including 640 mg EPA and 480 mg DHA, during non-surgical periodontal treatment. Receives: Dietary Supplement: Omega-3 (EPA+DHA) | |
| No supplementation | Patients who underwent non-surgical periodontal treatment without receiving resveratrol or omega-3 supplementation Receives: Dietary Supplement: No supplementation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical attachment level (CAL)
Clinical attachment level (CAL) was measured in millimeters using a Williams periodontal probe as the distance between the cementoenamel junction (CEJ) and the base of the periodontal pocket. In sites with gingival recession, the distance from the CEJ to the gingival margin was incorporated into the CAL measurement. Measurements were recorded at six sites per tooth: mesiobuccal/mesiolabial, mid-buccal/midlabial, distobuccal/distolabial, mesiolingual/mesiopalatal, mid-lingual/mid-palatal, and distolingual/distopalatal sites.
Measured: Baseline, 1 month, and 3 months
Secondary outcomes (4)
Probing Pocket Depth (PPD)
Probing pocket depth (PPD) was measured in millimeters using a Williams periodontal probe as the distance from the gingival margin to the base of the periodontal pocket. Measurements were recorded at six sites per tooth: mesiobuccal/mesiolabial, mid-buccal/midlabial, distobuccal/distolabial, mesiolingual/mesiopalatal, mid-lingual/mid-palatal, and distolingual/distopalatal sites.
Measured: Baseline, 1 month, and 3 months
Plaque Index (PI)
Plaque accumulation was assessed using the Plaque Index described by Silness and Löe (1964). Plaque scores were recorded at six sites per tooth: mesiobuccal/mesiolabial, mid-buccal/mid-labial, distobuccal/distolabial, mesiolingual/mesiopalatal, mid-lingual/mid-palatal, and distolingual/distopalatal sites.
Measured: Baseline, 1 month, and 3 months
Gingival Index (GI)
Gingival inflammation was assessed using the Gingival Index described by Löe and Silness (1963). Gingival Index scores were recorded at six sites per tooth: mesiobuccal/mesiolabial, mid-buccal/mid-labial, distobuccal/distolabial, mesiolingual/mesiopalatal, mid-lingual/mid-palatal, and distolingual/distopalatal sites.
Measured: Baseline, 1 month, and 3 months
Bleeding on Probing (BOP)
Gingival bleeding was assessed using the bleeding on probing method described by Ainamo and Bay (1975). The gingival crevice was gently probed, and sites showing bleeding within 10 seconds after probing were recorded as positive (+), whereas sites without bleeding within 10 seconds were recorded as negative (-). Gingival bleeding was assessed at four sites per tooth: mesiobuccal/mesiolabial, mid-buccal/mid-labial, distobuccal/distolabial, and mid-lingual/mid-palatal sites. The percentage of bleeding sites among the total number of examined sites was calculated.
Measured: Baseline, 1 month, and 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2026
- Study start1 Jan 2025
- Primary completion15 Mar 2027 (estimated)
- Study completion15 Mar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PeriodontitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Izmir Katip Celebi University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Pelin Akpak, Izmir Katip Celebi University
- Investigators
- MEHMET SAĞLAM, Professor, Study director, Izmir Katip Celebi University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07827391
- Sponsor's protocol ID
- 2026-SAEK-0562
- Status last verified
- Sep 2026
- First submitted
- 14 Sep 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared with other researchers because of participant privacy and confidentiality considerations and the retrospective nature of the study.
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Retrospective Comparative Evaluation of the Effects of Adjunctive Omega-3 and Resveratrol Supplementation to Non-Surgical Periodontal Therapy on Clinical Periodontal Parameters in Systemically Healthy Patients With Periodontitis.
- ClinicalTrials.gov ID
- NCT07827391
- Acronym / sponsor ID
- 2026-SAEK-0562
- Conditions
- Periodontitis
- Keywords
- Resveratrol, Omega-3 fatty acid, Periodontitis, Non-surgical periodontal treatment, Clinical attachment level
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Izmir Katip Celebi UniversityUniversity, hospital or other
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 15 Mar 2027 (estimated)
- Study completion
- 15 Mar 2028 (estimated)
- First posted
- 18 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This retrospective comparative study aims to evaluate the association of adjunctive resveratrol and omega-3 supplementation with clinical periodontal parameters in patients with periodontitis who received non-surgical periodontal treatment. A total of 60 systemically healthy, non-smoking patients will be evaluated based on their clinical records and categorized into three groups according to their documented supplementation status: a resveratrol group that received non-surgical periodontal treatment with adjunctive resveratrol supplementation (n=20), an omega-3 group that received non-surgical periodontal treatment with adjunctive omega-3 supplementation (n=20), and a non-supplemented group that received non-surgical periodontal treatment alone (n=20). Clinical periodontal parameters, including probing pocket depth, clinical attachment level, plaque index, gingival index, and bleeding on probing, will be evaluated at baseline and at 1 and 3 months after non-surgical periodontal treatment. The study aims to compare clinical periodontal outcomes among the three groups and to assess whether adjunctive resveratrol or omega-3 supplementation is associated with differences in clinical periodontal parameters compared with non-surgical periodontal treatment alone.
Detailed description
This retrospective comparative study aims to evaluate the association of resveratrol and omega-3 supplementation, administered as adjuncts to non-surgical periodontal treatment, with clinical periodontal outcomes in patients with periodontitis. The study also aims to compare the clinical periodontal outcomes associated with these two supplementation approaches with those observed following non-surgical periodontal treatment without supplementation and to compare the two supplementation groups with each other.
Periodontitis is a chronic inflammatory disease in which microbial dental biofilm and the host inflammatory response contribute to periodontal tissue breakdown. Accordingly, periodontal treatment primarily aims to control the subgingival microbial burden and reduce periodontal inflammation, thereby improving clinical periodontal conditions. In addition to mechanical periodontal treatment, adjunctive approaches with anti-inflammatory and antioxidant properties have been investigated for their potential association with differences in clinical periodontal outcomes.
Omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been investigated in the context of periodontal inflammation. These fatty acids may influence inflammatory processes and the resolution of inflammation through their involvement in the production of lipid mediators, including specialized pro-resolving mediators such as resolvins, protectins, and maresins. Resveratrol is a naturally occurring polyphenolic compound with reported antioxidant and anti-inflammatory properties. Its potential biological effects have been associated with the regulation of inflammatory signaling pathways and oxidative stress. These biological properties provide a rationale for investigating the clinical periodontal outcomes associated with resveratrol and omega-3 supplementation when used as adjuncts to non-surgical periodontal treatment.
Clinical records of 60 systemically healthy, non-smoking patients diagnosed with periodontitis will be retrospectively reviewed. Based on the documented supplementation status in their clinical records, patients will be classified into three groups, with 20 patients in each group. The resveratrol group will consist of patients who received resveratrol supplementation in addition to non-surgical periodontal treatment. The omega-3 group will consist of patients who received omega-3 supplementation in addition to non-surgical periodontal treatment. The non-supplemented control group will consist of patients who received non-surgical periodontal treatment alone.
Patients with a history of periodontal treatment within the previous 6 months, use of antibiotics, anti-inflammatory agents, or systemic corticosteroids within the previous 6 months, or a history of systemic disease will be excluded from the study.
Clinical periodontal parameters recorded at baseline and at 1 and 3 months after non-surgical periodontal treatment will be evaluated. The evaluated parameters will include probing pocket depth, clinical attachment level, plaque index, gingival index, and bleeding on probing.
The primary objective of the study is to compare clinical periodontal outcomes among the resveratrol, omega-3, and non-supplemented control groups. The study will also evaluate whether adjunctive resveratrol or omega-3 supplementation is associated with differences in clinical periodontal outcomes compared with non-surgical periodontal treatment alone. In addition, the study will compare clinical periodontal outcomes between the resveratrol and omega-3 supplementation groups. The study will provide a clinical comparison of periodontal outcomes among patients receiving non-surgical periodontal treatment with or without adjunctive supplementation.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Trans-resveratrol | – | Dietary Supplement: trans-resveratrolPatients who received trans-resveratrol supplementation at a dose of 250 mg twice daily (500 mg/day total) as an adjunct to non-surgical periodontal treatment. |
| Omega-3 fatty acids | – | Dietary Supplement: Omega-3 (EPA+DHA)Patients who received omega-3 fatty acid supplementation at a total dose of 1320 mg, including 640 mg EPA and 480 mg DHA, during non-surgical periodontal treatment. |
| No supplementation | – | Dietary Supplement: No supplementationPatients who underwent non-surgical periodontal treatment without receiving resveratrol or omega-3 supplementation |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consists of patients aged 18-65 years who were diagnosed with periodontitis and met the predefined eligibility criteria. A total of 60 patients were included in the study and categorized into three groups according to their recorded supplementation status: a trans-resveratrol supplementation group, an omega-3 supplementation group, and a non-supplemented control group receiving non-surgical periodontal treatment without resveratrol or omega-3 supplementation. All patients received non-surgical periodontal treatment.
Key inclusion criteria (8 listed)
- Presence of at least 20 natural permanent teeth,
- Age between 18 and 65 years,
- Non-smoker status,
- No use of antibiotics, anti-inflammatory drugs, or systemic corticosteroids within the previous 6 months,
- No known history of hypersensitivity or allergic reactions to resveratrol, omega-3 fatty acids, or dietary supplements containing these components,
Key exclusion criteria (8 listed)
- Presence of fewer than 20 natural permanent teeth,
- Age younger than 18 years or older than 65 years,
- Current smoking,
- Use of antibiotics, anti-inflammatory drugs, or systemic corticosteroids within the previous 6 months,
- Known hypersensitivity or allergic reactions to resveratrol, omega-3 fatty acids, or dietary supplements containing these components,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| trans-resveratrolTrans-resveratrol supplementation at a dose of 250 mg twice daily (500 mg/day total) during non-surgical periodontal treatment. | Dietary supplement | Trans-resveratrol |
| Omega-3 (EPA+DHA)Omega-3 fatty acid supplementation at a total daily dose of 1320 mg, including 640 mg EPA and 480 mg DHA, during non-surgical periodontal treatment. | Dietary supplement | Omega-3 fatty acids |
| No supplementationPatients who underwent non-surgical periodontal treatment without receiving resveratrol or omega-3 fatty acid supplementation during the treatment period | Dietary supplement | No supplementation |
Primary outcome
Clinical attachment level (CAL)
Time frame: Baseline, 1 month, and 3 months
Clinical attachment level (CAL) was measured in millimeters using a Williams periodontal probe as the distance between the cementoenamel junction (CEJ) and the base of the periodontal pocket. In sites with gingival recession, the distance from the CEJ to the gingival margin was incorporated into the CAL measurement. Measurements were recorded at six sites per tooth: mesiobuccal/mesiolabial, mid-buccal/midlabial, distobuccal/distolabial, mesiolingual/mesiopalatal, mid-lingual/mid-palatal, and distolingual/distopalatal sites.
4 secondary outcomes
Probing Pocket Depth (PPD)
Time frame: Baseline, 1 month, and 3 months
Plaque Index (PI)
Time frame: Baseline, 1 month, and 3 months
Gingival Index (GI)
Time frame: Baseline, 1 month, and 3 months
Bleeding on Probing (BOP)
Time frame: Baseline, 1 month, and 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared with other researchers because of participant privacy and confidentiality considerations and the retrospective nature of the study.
Related trials for Periodontitis
Recruiting
Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.
Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis
Recruiting
Probiotics Versus Antibiotics as an Adjuvant to Non-surgical Periodontal Treatment Among Smokers With Stage II, Grade B Periodontitis
Probiotics, Antibiotics
Recruiting
Effects of Different Activation Techniques on Antimicrobial Photodynamic Therapy in Apical Periodontitis
Apical Periodontitis, Endodontic Retreatment
Recruiting
Ozone Gel Versus Chlorohexidine Gel as an Adjunct to Non-Surgical Treatment of Stage II Periodontitis Grade B Among Smokers Patients
Ozone Gel, Chlorohexidine Gel
Not yet recruiting
Post-operative Pain and Clinical Outcome After Single-cone Obturation With a Calcium Silicate-based Versus Epoxy Resin Sealer
Post Operative Pain, Acute, Irreversible Pulpitis (Toothache)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
MEHMET SAĞLAM, Professor study director
Izmir Katip Celebi University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Periodontitis, run by Izmir Katip Celebi University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical attachment level (CAL) (time frame: Baseline, 1 month, and 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.